These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 39429779)

  • 1. Cohort-specific boolean models highlight different regulatory modules during Parkinson's disease progression.
    Hemedan AA; Satagopam V; Schneider R; Ostaszewski M
    iScience; 2024 Oct; 27(10):110956. PubMed ID: 39429779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stochastic Boolean networks: an efficient approach to modeling gene regulatory networks.
    Liang J; Han J
    BMC Syst Biol; 2012 Aug; 6():113. PubMed ID: 22929591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancements in Genetic and Biochemical Insights: Unraveling the Etiopathogenesis of Neurodegeneration in Parkinson's Disease.
    Ratan Y; Rajput A; Pareek A; Pareek A; Jain V; Sonia S; Farooqui Z; Kaur R; Singh G
    Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of Boolean modeling to study the dynamics of a complex disease and therapeutics responses.
    Hemedan AA; Schneider R; Ostaszewski M
    Front Bioinform; 2023; 3():1189723. PubMed ID: 37325771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Approaches to Early Parkinson's Disease Subtyping.
    Hu M; Skjærbæk C; Borghammer P
    J Parkinsons Dis; 2024; 14(s2):S297-S306. PubMed ID: 39331104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Force Platform-Based Intervention Program for Individuals Suffering with Neurodegenerative Diseases like Parkinson.
    Ujjan JA; Morani W; Memon N; Mohanasundaram S; Nuhmani S; Singh BK
    Comput Math Methods Med; 2022; 2022():1636263. PubMed ID: 35082910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-nucleus multi-omics of Parkinson's disease reveals a glutamatergic neuronal subtype susceptible to gene dysregulation via alteration of transcriptional networks.
    Shwab EK; Gingerich DC; Man Z; Gamache J; Garrett ME; Crawford GE; Ashley-Koch AE; Serrano GE; Beach TG; Lutz MW; Chiba-Falek O
    Acta Neuropathol Commun; 2024 Jul; 12(1):111. PubMed ID: 38956662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The interplay between gut microbiota and the brain-gut axis in Parkinson's disease treatment.
    Jia X; Wang Q; Liu M; Ding JY
    Front Neurol; 2024; 15():1415463. PubMed ID: 38867886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of key immune
    Huang Y; Wang A; Wang F; Xu Y; Zhang W; Shi F; Wang S
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Feb; 49(2):207-219. PubMed ID: 38755717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What can the treatment of Parkinson's disease learn from dementia care; applying a bio-psycho-social approach to Parkinson's disease.
    Gibson G
    Int J Older People Nurs; 2017 Dec; 12(4):. PubMed ID: 28685944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationships between probabilistic Boolean networks and dynamic Bayesian networks as models of gene regulatory networks.
    Lähdesmäki H; Hautaniemi S; Shmulevich I; Yli-Harja O
    Signal Processing; 2006 Apr; 86(4):814-834. PubMed ID: 17415411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cortical morphological alterations in cognitively normal Parkinson's disease with severe hyposmia.
    Li J; Xu Y; Liu X; Yang F; Fan W
    Brain Res; 2024 Dec; 1844():149150. PubMed ID: 39127119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From mitochondrial dysfunction to neuroinflammation in Parkinson's disease: Pathogenesis and mitochondrial therapeutic approaches.
    Ebadpour N; Mahmoudi M; Kamal Kheder R; Abavisani M; Baridjavadi Z; Abdollahi N; Esmaeili SA
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113015. PubMed ID: 39222583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comprehensive Review on Repurposing the Nanocarriers for the Treatment of Parkinson's Disease: An Updated Patent and Clinical Trials.
    Khan S; Haider MF
    CNS Neurol Disord Drug Targets; 2024 Oct; ():. PubMed ID: 39400019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational systems biology approaches for Parkinson's disease.
    Glaab E
    Cell Tissue Res; 2018 Jul; 373(1):91-109. PubMed ID: 29185073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic analysis of Probabilistic Boolean Network for fMRI study in Parkinson's disease.
    Ma Z; Wang ZJ
    Annu Int Conf IEEE Eng Med Biol Soc; 2008; 2008():161-4. PubMed ID: 19162618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Parkinson's disease PACE subtypes and repurposing treatments through integrative analyses of multimodal data.
    Su C; Hou Y; Xu J; Xu Z; Zhou M; Ke A; Li H; Xu J; Brendel M; Maasch JRMA; Bai Z; Zhang H; Zhu Y; Cincotta MC; Shi X; Henchcliffe C; Leverenz JB; Cummings J; Okun MS; Bian J; Cheng F; Wang F
    NPJ Digit Med; 2024 Jul; 7(1):184. PubMed ID: 38982243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implicit methods for probabilistic modeling of Gene Regulatory Networks.
    Garg A; Banerjee D; De Micheli G
    Annu Int Conf IEEE Eng Med Biol Soc; 2008; 2008():4621-7. PubMed ID: 19163746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neurophysiological brain-fingerprint of Parkinson's disease.
    da Silva Castanheira J; Wiesman AI; Hansen JY; Misic B; Baillet S; ;
    medRxiv; 2023 Dec; ():. PubMed ID: 36798232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leveraging genetic diversity to understand monogenic Parkinson's disease's landscape in AfrAbia.
    Mohamed W
    Am J Neurodegener Dis; 2023; 12(4):108-122. PubMed ID: 37736165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.